

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF ONESOURCE SPECIALTY PHARMA LIMITED (FORMERLY KNOWN AS STELIS BIOPHARMA LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **OneSource Specialty Pharma Limited** ("the Company"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement includes the results for the quarter ended June 30, 2024, which have been prepared by the Management from the books of account, which is neither audited nor reviewed by us. Our Conclusion on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)

Sandeep  
Ramesh Kukreja

Digitally signed by  
Sandeep Ramesh Kukreja  
Date: 2025.08.04 19:23:23  
+05'30'

**Sandeep Kukreja**  
Partner

(Membership No. 220411)  
(UDIN: 25220411BMOQED8078)

Place: Bengaluru  
Date: August 4, 2025

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)

Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703

Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India

CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: [info@onesourcecdmo.com](mailto:info@onesourcecdmo.com)

Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2025

Rs. in Million, except per share data

Sl No	Particulars	Quarter ended			Year ended
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		(Unaudited)	(Refer note 8)	(Refer note 3)	(Audited)
<b>A.</b>	<b>Continuing Operations</b>				
	<b>Income</b>				
1	Revenue from operations	3,210.12	4,774.14	2,400.26	12,995.89
2	Other income	52.55	39.09	39.99	176.82
3	<b>Total income (1+2)</b>	<b>3,262.67</b>	<b>4,813.23</b>	<b>2,440.25</b>	<b>13,172.71</b>
4	<b>Expenses</b>				
	(a) Cost of materials consumed	508.48	945.96	796.05	3,301.74
	(b) Changes in inventories of finished goods and work-in-progress	49.37	(89.05)	27.97	26.11
	(c) Consumables	367.02	265.92	242.52	753.98
	(d) Employee benefits expenses	581.52	509.44	527.70	2,148.00
	(e) Finance costs	270.31	323.94	412.26	1,616.50
	(f) Depreciation and amortisation expenses	332.84	335.94	335.03	1,345.12
	(g) Other expenses	904.98	772.31	703.42	3,073.31
	<b>Total expenses (4)</b>	<b>3,014.52</b>	<b>3,064.46</b>	<b>3,044.95</b>	<b>12,264.76</b>
5	<b>Profit/(Loss) before exceptional items and tax (3-4)</b>	<b>248.15</b>	<b>1,748.77</b>	<b>(604.70)</b>	<b>907.95</b>
6	Exceptional items - loss (net) (Refer note 5)	-	-	(49.51)	(1,122.50)
7	<b>Profit/(Loss) before tax (5+6)</b>	<b>248.15</b>	<b>1,748.77</b>	<b>(654.21)</b>	<b>(214.55)</b>
8	<b>Income tax expense</b>				
	Current tax	-	-	-	-
	Deferred tax	-	-	(414.55)	(414.55)
	<b>Total tax expense</b>	<b>-</b>	<b>-</b>	<b>(414.55)</b>	<b>(414.55)</b>
9	<b>Profit/(Loss) after tax (7-8)</b>	<b>248.15</b>	<b>1,748.77</b>	<b>(239.66)</b>	<b>200.00</b>
<b>B.</b>	<b>Discontinued Operations</b>				
	(i) Loss from Discontinued Operations (Refer note 4)	-	(6.90)	-	(6.90)
	(ii) Gain on disposal of assets / settlement of liabilities attributable to the discontinued operations (net)	-	-	-	-
	(iii) Tax expense of discontinued operations	-	-	-	-
10	<b>Profit/(Loss) after tax from discontinued operations</b>	<b>-</b>	<b>(6.90)</b>	<b>-</b>	<b>(6.90)</b>
	Profit/(Loss) for the period/year (9+10)	<b>248.15</b>	<b>1,741.87</b>	<b>(239.66)</b>	<b>193.10</b>
11	<b>Other Comprehensive Income</b>				
	<b>Items that will not be reclassified to statement of profit and loss</b>				
	- Remeasurements of post employment benefit obligations- gain/(loss)	-	0.79	(15.22)	(29.65)
	- Income tax relating to these items	-	-	-	-
	<b>Total other comprehensive income/(loss)</b>	<b>-</b>	<b>0.79</b>	<b>(15.22)</b>	<b>(29.65)</b>
12	<b>Total comprehensive income/(loss) for the period/year (10+11)</b>	<b>248.15</b>	<b>1,742.66</b>	<b>(254.88)</b>	<b>163.45</b>
13	<b>Paid-up equity share capital (of Rs. 1/- each)</b>	114.46	114.43	108.16	114.43
14	<b>Reserves (Other Equity)</b>				59,086.58
15	<b>Earnings/ (Loss) per share (of Rs. 1/- each) (for continuing operations):</b>	<b>(not annualised)</b>	<b>(not annualised)</b>	<b>(not annualised)</b>	<b>(annualised)</b>
	- Basic	2.17	15.28	(2.22)	1.81
	- Diluted	2.16	15.25	(2.22)	1.81
	<b>Earnings/ (Loss) per share (of Rs. 1/- each) (for discontinued operations):</b>				
	- Basic	-	(0.06)	-	(0.06)
	- Diluted	-	(0.06)	-	(0.06)
	<b>Earnings/ (Loss) per share (of Rs. 1/- each) (for total operations):</b>				
	- Basic	2.17	15.22	(2.22)	1.75
	- Diluted	2.16	15.19	(2.22)	1.75

See accompanying notes to the Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2025

**OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)****Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703****Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India****CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: [info@onesourcecdmo.com](mailto:info@onesourcecdmo.com)****Notes to the Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2025**

- 1 In terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, ("Listing Requirements"), as amended, the Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2025 ("Statement") of OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited) ('the Company') has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 4, 2025. The aforesaid results for the quarter ended June 30, 2025 has been reviewed by Deloitte Haskins & Sells, the statutory auditors of the Company, who have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30, 2025.
- 2 The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Listing Requirements, as amended.
- 3 The Standalone Financial Information for the quarter ended June 30, 2024 included in the Statement have not been subject to an audit or review by our statutory auditors. However, the Management has exercised necessary due diligence to ensure that the financial information for the said period provide a true and fair view of the Company's affairs.
- 4 During the year ended March 31 2024, the Company entered into a Business Transfer Agreement with Syngene International Limited ("Syngene") for sale of Unit-3 (multimodal facility) on a slump sale basis. During the quarter ended December 31, 2023, parties as per the BTA have completed the transaction related to divestment of Unit-3.

The Company has classified the Unit-3 multimodal facility related operations which is transferred by the Company to Syngene as discontinued operations in line with the requirements of Ind AS 105 - Non-current assets held for sale and discontinued operations.

Syngene withheld Rs. 100 million which is to be paid post completion of certain closing conditions. During the year ended March 31, 2024, the Management accounted for a provision of Rs. 50 million which was the Management's best estimate of the recoverability of the pending amount. During the previous year, the Company has received Rs. 43.10 million out of the retained amount and has accounted for an additional provision of Rs. 6.90 million and accordingly have disclosed under discontinued operations.

**5 Exceptional items (net)**

Particulars	Rs. in Million		
	Quarter ended		Year ended
	June 30, 2025	March 31, 2025	June 30, 2024
			March 31, 2025
Provision/(reversal) towards investment/trade receivables in subsidiaries/step-down subsidiary (net)	-	-	4.51
Business combination, listing and post-merger integration related expenses*	-	-	45.00
<b>Total</b>	<b>-</b>	<b>-</b>	<b>49.51</b>
			<b>1,122.50</b>

\* Pertains to expenses incurred towards the Scheme of arrangement and consequent listing of the Company, expenses majorly includes legal and professional fees, provisional stamp duty expenses, one-time incentive and awards to employees and interest on prepayment of debt pursuant to the Scheme of arrangement.

- 6 During the year ended March 31, 2025 the Company has fully repaid its listed non-convertible debentures. The security against these debentures secured by a pari passu charge over certain specified movable assets, as well as an exclusive charge on specific fixed deposits with the bank are released during the year ended March 31, 2025. Pursuant to delisting of listed debentures from BSE Limited during the quarter, the Company concluded that reporting under Regulation 52 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, ("Listing Requirements"), as amended, is not applicable for the quarter ended 30 June 2025.

**OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)**

**Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703**

**Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India**

**CIN: L74140MH2007PLC432497, Website : <https://www.onesourcecdmo.com>, Mail: [info@onesourcecdmo.com](mailto:info@onesourcecdmo.com)**

**Notes to the Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2025**

- 7 The Company publishes these Unaudited Standalone Financial Results along with Unaudited Consolidated Financial Results. In accordance with Ind AS 108, 'Operating Segments', the Company has disclosed the segment information in the unaudited consolidated financial results.
- 8 The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect to full financial year and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which are subjected to limited review.

**For and on behalf of Board of Directors of OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited)**

**NEERAJ SHARMA**  
Digitally signed by  
NEERAJ SHARMA  
Date: 2025.08.04  
18:56:11 +05'30'

**Neeraj Sharma**  
Managing Director  
DIN : 09402652

Place : Bengaluru  
Date : August 4, 2025